EIF2A and acute myeloid leukemia: Although featuring a different molecular target compared to ATO, we speculated that plecstatin-1 may be a suitable candidate for normalization therapy in AML in combination with inducers of differentiation, due to the overlapping ROS-generation and ISR induction, i.e., overlapping stress responses in cancer cells that rely on phosphorylation of eIF2α (Wernitznig et al., 2020).